Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease

Data Availability

The datasets generated and/or analyzed in this paper are publicly available. Data from the CGMS analyzed for the lung function pre- and post-modulator treatment are available from the Canadian CF registry at https://www.cysticfibrosis.ca/our-programs/cf-registry/requesting-canadian-cf-registry-data; the functional data and RNA-seq data from CGMS is available from the CFIT program at https://lab.research.sickkids.ca/cfit/cystic-fibrosis-patients-families-researchers/, and the paired cultured and fresh naive HNE and HBE is available at GEO (GSE172232). The US PROSPECT data were obtained through application to the US CFF at https://www.cff.org/Research/Researcher-Resources/ and the study is registered on https://clinicaltrials.gov/ct2/show/NCT02477319. The single-cell RNA-sequencing data are downloaded from the Human Lung Cell Atlas at http://hlca.ds.czbiohug.org. The summary statistics for the pheWAS study is available at https://atlas.ctglab.nl/PheWAS and the meconium ileus association results that have been used for colocalization analysis can be downloaded at https://lab.research.sickkids.ca/strug/publications-software/. The data used for the COPD analysis are available through application to the UK Biobank.